OncoMatch/Clinical Trials/NCT06274047
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
Is NCT06274047 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Apalutamide and Androgen Deprivation Therapy for androgen axis suppression.
Treatment: Apalutamide · Androgen Deprivation Therapy — 1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radiation therapy for prostate cancer, as compared to standard therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: testosterone suppression (GnRH agonist, GnRH antagonist, anti-androgen)
Exception: participants with testosterone recovery after post-prostatectomy testosterone suppression are eligible (testosterone recovery defined as total testosterone > 190 ng/dL) regardless of how long their testosterone was suppressed
Use of post-prostatectomy testosterone suppression prior to registration (use of GnRH agonist or antagonist, with or without an anti-androgen). However, participants with testosterone recovery after post-prostatectomy testosterone suppression are eligible (testosterone recovery defined as total testosterone > 190 ng/dL) regardless of how long their testosterone was suppressed.
Lab requirements
Blood counts
Platelet count ≥ 100,000/µL; Hemoglobin ≥ 9 g/dL
Kidney function
eGFR ≥ 30 mL/min using MDRD Formula
Liver function
Bilirubin ≤1.5 x ULN (Gilbert's syndrome exception: if total bilirubin >1.5 x ULN, direct bilirubin ≤ 1.5 x ULN); AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN; Serum Albumin > 3.0 g/dL
Demonstrate adequate organ function as defined in the table below. Platelet count ≥ 100,000/µL; Hemoglobin ≥ 9 g/dL; eGFR ≥ 30 mL/min using MDRD Formula; Bilirubin ≤1.5 x ULN (Gilbert's syndrome exception: if total bilirubin >1.5 x ULN, direct bilirubin ≤ 1.5 x ULN); AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN; Serum Albumin > 3.0 g/dL; Serum potassium ≥ 3.5 mmol/L
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Kansas Medical Center · Kansas City, Kansas
- Dana-Farber Cancer Institute · Boston, Massachusetts
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify